{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:21:32Z","timestamp":1791296492457,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T00:00:00Z","timestamp":1349481600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2407-12-458","type":"journal-article","created":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T18:14:20Z","timestamp":1349547260000},"source":"Crossref","is-referenced-by-count":61,"title":["Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan"],"prefix":"10.1186","volume":"12","author":[{"given":"Stephen","family":"Hiscox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bedanta","family":"Baruah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bellerby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy","family":"Goddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaruhi","family":"Poghosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert I","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barrett-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,6]]},"reference":[{"key":"3442_CR1","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2011","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011, 378: 771-784.","journal-title":"Lancet"},{"key":"3442_CR2","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"(EBCTCG) EBCTCG","year":"2005","unstructured":"(EBCTCG) EBCTCG: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717.","journal-title":"Lancet"},{"key":"3442_CR3","doi-asserted-by":"publisher","first-page":"1024s","DOI":"10.1158\/1078-0432.CCR-05-2127","volume":"12","author":"M Dowsett","year":"2006","unstructured":"Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, et al: Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006, 12: 1024s-1030s. 10.1158\/1078-0432.CCR-05-2127.","journal-title":"Clin Cancer Res"},{"key":"3442_CR4","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003, 349: 1793-1802. 10.1056\/NEJMoa032312.","journal-title":"N Engl J Med"},{"key":"3442_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11154-007-9033-5","volume":"8","author":"RI Nicholson","year":"2007","unstructured":"Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM, Gee JM: Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord. 2007, 8: 241-253. 10.1007\/s11154-007-9033-5.","journal-title":"Rev Endocr Metab Disord"},{"key":"3442_CR6","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1210\/en.2002-220620","volume":"144","author":"JM Knowlden","year":"2003","unstructured":"Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI: Elevated levels of epidermal growth factor receptor\/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003, 144: 1032-1044. 10.1210\/en.2002-220620.","journal-title":"Endocrinology"},{"key":"3442_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1517\/14728222.2011.561201","volume":"15","author":"S Hiscox","year":"2011","unstructured":"Hiscox S, Barrett-Lee P, Nicholson RI: Therapeutic targeting of tumor-stroma interactions. Expert Opin Ther Targets. 2011, 15: 609-621.","journal-title":"Expert Opin Ther Targets"},{"key":"3442_CR8","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1677\/erc.1.01270","volume":"13","author":"S Hiscox","year":"2006","unstructured":"Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C, Nicholson RI: Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocr Relat Cancer. 2006, 13: 1085-1099. 10.1677\/erc.1.01270.","journal-title":"Endocr Relat Cancer"},{"key":"3442_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ijc.21355","volume":"118","author":"S Hiscox","year":"2006","unstructured":"Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI: Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2006, 118: 290-301. 10.1002\/ijc.21355.","journal-title":"Int J Cancer"},{"key":"3442_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1004","volume":"4","author":"H Ponta","year":"2003","unstructured":"Ponta H, Sherman L, Herrlich PA: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003, 4: 33-45. 10.1038\/nrm1004.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3442_CR11","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1101\/gad.242602","volume":"16","author":"V Orian-Rousseau","year":"2002","unstructured":"Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H: CD44 is required for two consecutive steps in HGF\/c-Met signaling. Genes Dev. 2002, 16: 3074-3086. 10.1101\/gad.242602.","journal-title":"Genes Dev"},{"key":"3442_CR12","doi-asserted-by":"publisher","first-page":"39703","DOI":"10.1074\/jbc.M204320200","volume":"277","author":"LY Bourguignon","year":"2002","unstructured":"Bourguignon LY, Singleton PA, Zhu H, Zhou B: Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem. 2002, 277: 39703-39712. 10.1074\/jbc.M204320200.","journal-title":"J Biol Chem"},{"key":"3442_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.canlet.2008.01.014","volume":"263","author":"Z Palyi-Krekk","year":"2008","unstructured":"Palyi-Krekk Z, Barok M, Kovacs T, Saya H, Nagano O, Szollosi J, Nagy P: EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. Cancer Lett. 2008, 263: 231-242. 10.1016\/j.canlet.2008.01.014.","journal-title":"Cancer Lett"},{"issue":"20","key":"3442_CR14","doi-asserted-by":"publisher","first-page":"17618","DOI":"10.1074\/jbc.M111.226563","volume":"286","author":"S Meran","year":"2011","unstructured":"Meran S, Luo DD, Simpson R, Martin J, Wells A, Steadman R, Phillips AO: Hyaluronan facilitates transforming growth factor-{beta}1 dependent proliferation via CD44 and epidermal growth factor-receptor interaction. J Biol Chem. 2011, 286 (20): 17618-17630. 10.1074\/jbc.M111.226563.","journal-title":"J Biol Chem"},{"key":"3442_CR15","doi-asserted-by":"publisher","first-page":"27913","DOI":"10.1074\/jbc.272.44.27913","volume":"272","author":"LY Bourguignon","year":"1997","unstructured":"Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L, Hung MC: Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem. 1997, 272: 27913-27918. 10.1074\/jbc.272.44.27913.","journal-title":"J Biol Chem"},{"key":"3442_CR16","doi-asserted-by":"publisher","first-page":"10233","DOI":"10.1158\/0008-5472.CAN-06-1464","volume":"66","author":"M Gotte","year":"2006","unstructured":"Gotte M, Yip GW: Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006, 66: 10233-10237. 10.1158\/0008-5472.CAN-06-1464.","journal-title":"Cancer Res"},{"key":"3442_CR17","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/0008-5472.CAN-11-3024","volume":"72","author":"M Tamada","year":"2012","unstructured":"Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T, Sugihara E, Onishi N, Yamamoto T, Yanagawa H, et al: Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res. 2012, 72: 1438-1448. 10.1158\/0008-5472.CAN-11-3024.","journal-title":"Cancer Res"},{"key":"3442_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.ajpath.2011.11.015","volume":"180","author":"YC Wang","year":"2012","unstructured":"Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, Lai HC: ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol. 2012, 180: 1159-1169. 10.1016\/j.ajpath.2011.11.015.","journal-title":"Am J Pathol"},{"key":"3442_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0002-9440(10)64757-8","volume":"156","author":"P Auvinen","year":"2000","unstructured":"Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM: Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol. 2000, 156: 529-536. 10.1016\/S0002-9440(10)64757-8.","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"3442_CR20","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1677\/erc.1.01005","volume":"12","author":"JM Gee","year":"2005","unstructured":"Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI: Epidermal growth factor receptor\/HER2\/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer. 2005, 12 (Suppl 1): S99-S111.","journal-title":"Endocr Relat Cancer"},{"key":"3442_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/mc.20766","volume":"50","author":"IH Koumakpayi","year":"2011","unstructured":"Koumakpayi IH, Le Page C, Delvoye N, Saad F, Mes-Masson AM: Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells. Mol Carcinog. 2011, 50: 901-912. 10.1002\/mc.20766.","journal-title":"Mol Carcinog"},{"key":"3442_CR22","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.cellsig.2012.01.002","volume":"24","author":"L Andrique","year":"2012","unstructured":"Andrique L, Fauvin D, El Maassarani M, Colasson H, Vannier B, Seite P: ErbB3(80 kDa), a nuclear variant of the ErbB3 receptor, binds to the Cyclin D1 promoter to activate cell proliferation but is negatively controlled by p14ARF. Cell Signal. 2012, 24: 1074-1085. 10.1016\/j.cellsig.2012.01.002.","journal-title":"Cell Signal"},{"key":"3442_CR23","doi-asserted-by":"publisher","first-page":"R50","DOI":"10.1186\/bcr1754","volume":"9","author":"IR Hutcheson","year":"2007","unstructured":"Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI: Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res. 2007, 9: R50-10.1186\/bcr1754.","journal-title":"Breast Cancer Res"},{"key":"3442_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0014-5793(99)00283-5","volume":"447","author":"JT Jones","year":"1999","unstructured":"Jones JT, Akita RW, Sliwkowski MX: Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 1999, 447: 227-231. 10.1016\/S0014-5793(99)00283-5.","journal-title":"FEBS Lett"},{"key":"3442_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","volume":"5","author":"MC Franklin","year":"2004","unstructured":"Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004, 5: 317-328. 10.1016\/S1535-6108(04)00083-2.","journal-title":"Cancer Cell"},{"key":"3442_CR26","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc1391","volume":"4","author":"BP Toole","year":"2004","unstructured":"Toole BP: Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004, 4: 528-539. 10.1038\/nrc1391.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3442_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10549-011-1865-8","volume":"133","author":"MA Ahmed","year":"2011","unstructured":"Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M, Ellis IO: A CD44(-)\/CD24 (+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat. 2011, 133 (3): 979-995.","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"3442_CR28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1677\/erc.1.01054","volume":"12","author":"JM Gee","year":"2005","unstructured":"Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M, et al: Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer. 2005, 12 (Suppl 1): S1-7.","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 1","key":"3442_CR29","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1677\/erc.1.01297","volume":"13","author":"S Hiscox","year":"2006","unstructured":"Hiscox S, Morgan L, Green T, Nicholson RI: Src as a therapeutic target in anti-hormone\/anti-growth factor-resistant breast cancer. Endocr Relat Cancer. 2006, 13 (Suppl 1): S53-59.","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"3442_CR30","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jcp.2011.090456","volume":"64","author":"S Ricardo","year":"2011","unstructured":"Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J: Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011, 64 (11): 937-946. 10.1136\/jcp.2011.090456.","journal-title":"J Clin Pathol"},{"key":"3442_CR31","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.4049\/jimmunol.0902566","volume":"185","author":"M Gordin","year":"2010","unstructured":"Gordin M, Tesio M, Cohen S, Gore Y, Lantner F, Leng L, Bucala R, Shachar I: c-Met and its ligand hepatocyte growth factor\/scatter factor regulate mature B cell survival in a pathway induced by CD74. J Immunol. 2010, 185: 2020-2031. 10.4049\/jimmunol.0902566.","journal-title":"J Immunol"},{"key":"3442_CR32","doi-asserted-by":"publisher","first-page":"30643","DOI":"10.1074\/jbc.M702573200","volume":"282","author":"PA Singleton","year":"2007","unstructured":"Singleton PA, Salgia R, Moreno-Vinasco L, Moitra J, Sammani S, Mirzapoiazova T, Garcia JG: CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1\/Rac1, dynamin 2, and cortactin. J Biol Chem. 2007, 282: 30643-30657. 10.1074\/jbc.M702573200.","journal-title":"J Biol Chem"},{"key":"3442_CR33","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1182\/blood-2009-04-219204","volume":"114","author":"M Tremmel","year":"2009","unstructured":"Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Heroult M, Augustin HG, Ponta H, Orian-Rousseau V: A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood. 2009, 114: 5236-5244. 10.1182\/blood-2009-04-219204.","journal-title":"Blood"},{"key":"3442_CR34","doi-asserted-by":"publisher","first-page":"48679","DOI":"10.1074\/jbc.M106759200","volume":"276","author":"LY Bourguignon","year":"2001","unstructured":"Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC: Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem. 2001, 276: 48679-48692. 10.1074\/jbc.M106759200.","journal-title":"J Biol Chem"},{"key":"3442_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/labinvest.2010.176","volume":"91","author":"H Hatano","year":"2011","unstructured":"Hatano H, Shigeishi H, Kudo Y, Higashikawa K, Tobiume K, Takata T, Kamata N: RHAMM\/ERK interaction induces proliferative activities of cementifying fibroma cells through a mechanism based on the CD44-EGFR. Lab Invest. 2011, 91: 379-391. 10.1038\/labinvest.2010.176.","journal-title":"Lab Invest"},{"key":"3442_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1023\/B:CLIN.0000037697.76011.1d","volume":"21","author":"S Hiscox","year":"2004","unstructured":"Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI: Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis. 2004, 21: 201-212.","journal-title":"Clin Exp Metastasis"},{"key":"3442_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.canlet.2008.10.022","volume":"275","author":"Y Zhao","year":"2009","unstructured":"Zhao Y, Planas-Silva MD: Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity. Cancer Lett. 2009, 275: 204-212. 10.1016\/j.canlet.2008.10.022.","journal-title":"Cancer Lett"},{"key":"3442_CR38","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jcb.22136","volume":"107","author":"S Soni","year":"2009","unstructured":"Soni S, Lin BT, August A, Nicholson RI, Kirsch KH: Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase\/Akt survival pathway in tamoxifen resistant breast cancer cells. J Cell Biochem. 2009, 107: 364-375. 10.1002\/jcb.22136.","journal-title":"J Cell Biochem"},{"key":"3442_CR39","doi-asserted-by":"publisher","first-page":"19426","DOI":"10.1074\/jbc.M610054200","volume":"282","author":"LY Bourguignon","year":"2007","unstructured":"Bourguignon LY, Gilad E, Peyrollier K: Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem. 2007, 282: 19426-19441. 10.1074\/jbc.M610054200.","journal-title":"J Biol Chem"},{"key":"3442_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12307-008-0017-0","volume":"2","author":"A Sadlonova","year":"2009","unstructured":"Sadlonova A, Bowe DB, Novak Z, Mukherjee S, Duncan VE, Page GP, Frost AR: Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron. 2009, 2: 9-21.","journal-title":"Cancer Microenviron"},{"key":"3442_CR41","first-page":"83","volume":"1","author":"SJ Cho","year":"2008","unstructured":"Cho SJ, Chae MJ, Shin BK, Kim HK, Kim A: Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment. Mol Med Report. 2008, 1: 83-88.","journal-title":"Mol Med Report"},{"key":"3442_CR42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF00665981","volume":"35","author":"N Normanno","year":"1995","unstructured":"Normanno N, Kim N, Wen D, Smith K, Harris AL, Plowman G, Colletta G, Ciardiello F, Salomon DS: Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res Treat. 1995, 35: 293-297. 10.1007\/BF00665981.","journal-title":"Breast Cancer Res Treat"},{"key":"3442_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1023\/A:1024929522376","volume":"80","author":"G Hudelist","year":"2003","unstructured":"Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, Czerwenka K: Co-expression of ErbB-family members in human breast cancer: Her-2\/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat. 2003, 80: 353-361. 10.1023\/A:1024929522376.","journal-title":"Breast Cancer Res Treat"},{"key":"3442_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1023\/A:1005845512804","volume":"45","author":"DW Visscher","year":"1997","unstructured":"Visscher DW, Sarkar FH, Kasunic TC, Reddy KB: Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia. Breast Cancer Res Treat. 1997, 45: 75-80. 10.1023\/A:1005845512804.","journal-title":"Breast Cancer Res Treat"},{"key":"3442_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/OTT.S21431","volume":"4","author":"P Van Phuc","year":"2011","unstructured":"Van Phuc P, Nhan PL, Nhung TH, Tam NT, Hoang NM, Tue VG, Thuy DT, Ngoc PK: Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. Onco Targets Ther. 2011, 4: 71-78.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"3442_CR46","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1541-7786.MCR-09-0237","volume":"9","author":"JW Cain","year":"2011","unstructured":"Cain JW, Hauptschein RS, Stewart JK, Bagci T, Sahagian GG, Jay DG: Identification of CD44 as a Surface Biomarker for Drug Resistance by Surface Proteome Signature Technology. Mol Cancer Res. 2011, 9 (5): 637-647. 10.1158\/1541-7786.MCR-09-0237.","journal-title":"Mol Cancer Res"},{"key":"3442_CR47","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semcancer.2008.03.007","volume":"18","author":"LY Bourguignon","year":"2008","unstructured":"Bourguignon LY: Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol. 2008, 18: 251-259. 10.1016\/j.semcancer.2008.03.007.","journal-title":"Semin Cancer Biol"},{"key":"3442_CR48","first-page":"1119","volume":"31","author":"ST Peng","year":"2007","unstructured":"Peng ST, Su CH, Kuo CC, Shaw CF, Wang HS: CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. Int J Oncol. 2007, 31: 1119-1126.","journal-title":"Int J Oncol"},{"issue":"2","key":"3442_CR49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ijc.26014","volume":"30","author":"H Urakawa","year":"2011","unstructured":"Urakawa H, Nishida Y, Wasa J, Arai E, Zhuo L, Kimata K, Kozawa E, Futamura N, Ishiguro N: Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer. 2011, 30 (2): 454-466.","journal-title":"Int J Cancer"},{"key":"3442_CR50","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2353\/ajpath.2007.060828","volume":"171","author":"K Hosono","year":"2007","unstructured":"Hosono K, Nishida Y, Knudson W, Knudson CB, Naruse T, Suzuki Y, Ishiguro N: Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol. 2007, 171: 274-286. 10.2353\/ajpath.2007.060828.","journal-title":"Am J Pathol"},{"key":"3442_CR51","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1158\/0008-5472.CAN-04-1622","volume":"65","author":"L Udabage","year":"2005","unstructured":"Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, Nilsson SK, Thompson EW, Brown TJ: Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res. 2005, 65: 6139-6150. 10.1158\/0008-5472.CAN-04-1622.","journal-title":"Cancer Res"},{"key":"3442_CR52","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.1158\/1078-0432.CCR-09-0479","volume":"15","author":"BP Toole","year":"2009","unstructured":"Toole BP: Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities. Clin Cancer Res. 2009, 15: 7462-7468. 10.1158\/1078-0432.CCR-09-0479.","journal-title":"Clin Cancer Res"},{"key":"3442_CR53","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/1535-7163.MCT-07-2383","volume":"7","author":"SB Wallach-Dayan","year":"2008","unstructured":"Wallach-Dayan SB, Rubinstein AM, Hand C, Breuer R, Naor D: DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Mol Cancer Ther. 2008, 7: 1615-1623. 10.1158\/1535-7163.MCT-07-2383.","journal-title":"Mol Cancer Ther"},{"key":"3442_CR54","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.clon.2005.02.007","volume":"17","author":"W Ma","year":"2005","unstructured":"Ma W, Deng Y, Zhou L: The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study. Clin Oncol (R Coll Radiol). 2005, 17: 258-263. 10.1016\/j.clon.2005.02.007.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"3442_CR55","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1158\/1078-0432.CCR-04-2184","volume":"11","author":"LK Diaz","year":"2005","unstructured":"Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ: CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res. 2005, 11: 3309-3314. 10.1158\/1078-0432.CCR-04-2184.","journal-title":"Clin Cancer Res"},{"key":"3442_CR56","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.yexmp.2008.12.003","volume":"86","author":"A Afify","year":"2009","unstructured":"Afify A, Purnell P, Nguyen L: Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol. 2009, 86: 95-100. 10.1016\/j.yexmp.2008.12.003.","journal-title":"Exp Mol Pathol"},{"key":"3442_CR57","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.2353\/ajpath.2007.070535","volume":"171","author":"A Ouhtit","year":"2007","unstructured":"Ouhtit A: Abd Elmageed ZY, Abdraboh ME, Lioe TF, Raj MH: In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am J Pathol. 2007, 171: 2033-2039. 10.2353\/ajpath.2007.070535.","journal-title":"Am J Pathol"},{"key":"3442_CR58","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1172\/JCI44540","volume":"121","author":"RL Brown","year":"2011","unstructured":"Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C: CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011, 121: 1064-1074. 10.1172\/JCI44540.","journal-title":"J Clin Invest"},{"key":"3442_CR59","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5301\/JBM.2011.6291","volume":"26","author":"AM Afify","year":"2011","unstructured":"Afify AM, Tate S, Durbin-Johnson B, Rocke DM, Konia T: Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Int J Biol Markers. 2011, 26: 50-57. 10.5301\/JBM.2011.6291.","journal-title":"Int J Biol Markers"},{"key":"3442_CR60","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1083\/jcb.121.6.1299","volume":"121","author":"SJ Neame","year":"1993","unstructured":"Neame SJ, Isacke CM: The cytoplasmic tail of CD44 is required for basolateral localization in epithelial MDCK cells but does not mediate association with the detergent-insoluble cytoskeleton of fibroblasts. J Cell Biol. 1993, 121: 1299-1310. 10.1083\/jcb.121.6.1299.","journal-title":"J Cell Biol"},{"key":"3442_CR61","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.4161\/cbt.8.16.8954","volume":"8","author":"L Morgan","year":"2009","unstructured":"Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R, Hiscox S: Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther. 2009, 8: 1550-1558. 10.4161\/cbt.8.16.8954.","journal-title":"Cancer Biol Ther"},{"key":"3442_CR62","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/ijc.2910590508","volume":"59","author":"JM Gee","year":"1994","unstructured":"Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI: Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer. 1994, 59: 619-628. 10.1002\/ijc.2910590508.","journal-title":"Int J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-458.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-458\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T09:07:33Z","timestamp":1562231253000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,6]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3442"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-458","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,6]]},"article-number":"458"}}